



IFW

1751

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on the date shown below:

INFORMATION DISCLOSURE
STATEMENT
Patent Application
Docket No. GJE-1080
Serial No. 10/580,769

March 14, 2007

David R. Saliwanchik

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1751
Applicant(s) : Christopher Iain Grainger
Serial No. : 10/580,769
Filed : May 26, 2006
For : Stabilisation of Viral Microparticles

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

The above-identified patent application was filed in the U.S. Patent Office as a national application under 35 USC §371. A copy of the International Search Report and copies of the references cited therein have been made available in the national stage file.

However, for the examiner's convenience, the applicant is attaching a copy of the International Search Report as well as copies of the documents cited therein. Also attached is Form PTO/SB/08 listing the references.

In accordance with 37 CFR §1.56, the applicant hereby requests that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

The applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

DRS/wrc

Attachments: Form PTO/SB/08 (3 pages)
International Search Report
Copies of references cited (17)



PTO/SB/08A (07-05)
Approved for use through 07/31/2006.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/580,769
Filing Date	May 26, 2006
First Named Inventor	Christopher Iain Grainger
Art Unit	1751
Examiner Name	Not yet assigned
Attorney Docket Number	GJE-1080

Sheet 1 of 3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	GB 2 395 900 A	06-09-2004	Elan Drug Delivery Limited	All	
	F2	WO 96/03978 A1	02-15-1996	Quadrant Holdings Cambridge Limited	All	
	F3	WO 99/55362 A1	11-04-1999	Genentech, Inc.	All	
	F4	WO 00/00215 A1	01-06-2000	Alliance Pharmaceutical Corp.	All	
	F5	WO 02/32398 A2	04-25-2002	Massachusetts Institute of Technology	All	
	F6	WO 02/066005 A1	08-29-2002	Cambridge Biostability Ltd.	All	
	F7					
	F8					
	F9					

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/580,769	
			Filing Date	May 26, 2006	
			First Named Inventor	Christopher Iain Grainger	
			Art Unit	1751	
			Examiner Name	Not yet assigned	
			Attorney Docket Number	GJE-1080	
Sheet	2	of	3		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	AGUADO, M.T. <i>et al.</i> , "Injectable solid vaccines: a role in future immunization?", <i>WHO Drug Information</i> , 1998, pages 68-69, Vol. 12, No. 2.	
	R2	BOEHM, G. <i>et al.</i> , "On Technological and Immunological Benefits of Multivalent Single-Injection Microsphere Vaccines," <i>Pharmaceutical Research</i> , September 2002, pages 1330-1336, Vol. 19, No. 9.	
	R3	CAMBRIDGE BIOSTABILITY LTD, "Technology Overview: Single Shot Stable Liquid Vaccines and Snapjet Delivery Technology," October 2003, pages 1-30, Retrieved from the Internet: < http://holdsworth.3ev.com/fileadmin/downloads/overview.doc >	
	R4	GRIBBON, E.M. <i>et al.</i> , "Stabilisation of Vaccines Using Trehalose (Q-T4) Technology," <i>Developments in Biological Standardization</i> , 1996, pages 193-199, Vol. 87.	
	R5	LICALSI, C. <i>et al.</i> , "Dry powder inhalation as a potential delivery method for vaccines," <i>Vaccine</i> , January 1999, pages 1796-1803, Vol. 17, Nos. 13-14.	
	R6	THE NEW TECHNOLOGIES WORKING GROUP OF THE GAVI RESEARCH AND DEVELOPMENT TASK FORCE, "Report Prepared for the Board of the Global Alliance for Vaccines and Immunization (GAVI)," May 30, 2003, pages 1-124, Retrieved from the Internet: < http://www.vaccinealliance.org/resources/NTWG_global.pdf >	
	R7	ROSER, B., "Trehalose Drying: A Novel Replacement for Freeze-Drying," <i>Biopharm.</i> , September 1991, pages 47-53, Vol. 4, No. 8.	
	R8	SMITH, D. <i>et al.</i> , "Evaluation of Novel Aerosol Formulations Designed for Mucosal Vaccination Against Influenza Virus," <i>Vaccine</i> , June 2003, pages 2805-2812, Vol. 21, Nos. 21-22.	
	R9	TAMEZ-GUERRA, P. <i>et al.</i> , "Storage stability of <i>Anagrapha falcifera</i> nucleopolyhedrovirus in spray-dried formulations," <i>Journal of Invertebrate Pathology</i> , January 2002, pages 7-16, Vol. 79, No. 1.	
	R10	WANG, L. <i>et al.</i> , "Basic immunological properties of spray-dried lipid microparticles developed for nasal and systemic administration of vaccines," <i>S.T.P. Pharma Sciences</i> , January 2002, pages 53-61, Vol. 12, No. 1.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/580,769
				Filing Date	May 26, 2006
				First Named Inventor	Christopher Iain Grainger
				Art Unit	1751
				Examiner Name	Not yet assigned
				Attorney Docket Number	GJE-1080
Sheet	3	of	3		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R11	WORRALL, E.E. <i>et al.</i> , "Xerovac: an ultra rapid method for the dehydration and preservation of live attenuated Rinderpest and Peste des Petits ruminants vaccines," <i>Vaccine</i> , 2001, pages 834-839, Vol. 19, Nos. 7-8.	
	R12		
	R13		
	R14		
	R15		
	R16		
	R17		
	R18		
	R19		
	R20		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.